Legal Representation
Attorney
Miriam D. Trudell
USPTO Deadlines
Next Deadline
1497 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20240123)
Due Date
January 23, 2030
Grace Period Ends
July 23, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
39 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 13, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Nov 13, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Nov 13, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| May 13, 2024 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Apr 24, 2024 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Apr 23, 2024 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Apr 23, 2024 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Jan 23, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Jan 23, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Nov 7, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Nov 7, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Nov 6, 2023 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| Oct 18, 2023 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Oct 18, 2023 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Oct 18, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Oct 5, 2023 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Oct 4, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 4, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 4, 2023 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Aug 6, 2023 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | Loading... |
| Jul 19, 2023 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Jul 19, 2023 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | Loading... |
| Jul 6, 2023 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Jul 6, 2023 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Jul 6, 2023 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Jun 5, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 3, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Apr 27, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 27, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Apr 2, 2023 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Nov 14, 2022 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Oct 27, 2022 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Oct 27, 2022 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Sep 2, 2022 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Sep 1, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Aug 24, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 26, 2022 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Feb 22, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Feb 17, 2022 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 001
Chemicals used in industry and science, in the nature of immune related chemicals for immune cell analysis, immune cell monitoring, immune cell detection and immune cell stimulation and immune related chemicals used in science in the nature of MHC monomer and multimer reagents, MR1 monomer and multimer reagents, CD1 monomer and multimer reagents, antibodies, antigen monomer and multimer reagents, reagents, diagnostic agents, control reagents, oligonucleotide conjugated multimer reagents in the nature of DNA/RNA oligo conjugated multimer reagents; diagnostic reagents for diagnostic being research use, other than medical and veterinary use, and scientific use; research diagnostic reagents for scientific use; diagnostic test materials for scientific and diagnostic, other than medical and veterinary, purposes, namely, diagnostic reagents and preparations, except for medical or veterinary use; diagnostic kits for scientific and diagnostic, other than medical and veterinary, purposes comprised of diagnostic reagents and preparations, except for medical or veterinary use and also comprised of immune related chemicals used in science, in the nature of MHC monomer and multimer reagents, MR1 monomer and multimer reagents, CD1 monomer and multimer reagents, antibodies, antigen monomer and multimer reagents, reagents, diagnostic agents, control reagents, oligonucleotide conjugated multimer reagents in the nature of DNA/RNA oligo conjugated multimer reagents; assays for research purposes; biochemical reagents for non- medical purposes, other than medical and veterinary; chemical and diagnostic preparations for analysis for research purposes related to vaccines and immunotherapy, cancer vaccines, borrelia vaccines, TB- vaccines, HIV-vaccines, CMV-vaccines and other vaccines, and for use in scientific research in connection with therapy and immunotherapy, in particular, for use in cancer therapy, cancer immunotherapy, for analysis of T-cell lymphoma, T-cell infiltration of solid tumors and tissue; chemical, and diagnostic preparations for analysis for research purposes related to analysis of infectious diseases, autoimmunity and for use in scientific research in connection with toxicological studies, transplantation, immune monitoring, and vaccines and T-cell monitoring; chemical reagents for other than medicinal and veterinary purposes
Class 005
Preparations for pharmaceutical purposes, namely, pharmaceutical preparations for the treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; preparations for medical purposes, namely, diagnostic preparations for medical purposes and medical preparations for treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; chemical-pharmaceutical preparations for treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T- cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; diagnostic preparations for medical purposes; vaccines; diagnostic preparations for analysis for medical purposes, hereunder for each of the abovementioned preparations for medical analysis of vaccines, immunotherapeutics and cellular therapies, in particular cancer vaccines and immunotherapeutics, borrelia vaccines, TB-vaccines, HIV- vaccines and CMV-vaccines, T-cell therapies, and for use in connection with cancer therapy or other therapy, for medical analysis and treatment of T- cell lymphoma, T-cell infiltration of solid tumors and tissue, and for infectious diseases; diagnostic preparations for analysis for medical purposes, hereunder for use in connection with toxicological studies, transplantation, immune monitoring, or vaccines and T-cell monitoring
Class 042
Scientific and technological services, namely, scientific research, analysis and testing in the fields of medicine, pharmaceuticals, the immune system, medical diagnostic analysis and vaccines; scientific research; scientific research services, namely, diagnostic services related to research; analysis of medicine, pharmaceuticals and vaccines of others to assure compliance with industry standards; industrial research services in the fields of medicine, pharmaceuticals, the immune system, medical diagnostic analysis and vaccines; basic scientific research and clinical scientific research, hereunder for medicine and vaccine development; product research and development in the field of diagnostic preparations
Additional Information
Design Mark
The mark consists of the stylized wording "IMMUDEX" wherein the letters are colored blue, and the dot of the letter "I" is colored orange.
Color Claim
The color(s) blue and orange is/are claimed as a feature of the mark.
Classification
International Classes
001
005
042